These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 28347225)

  • 1. Magnetic resonance imaging tumor regression shrinkage patterns after neoadjuvant chemotherapy in patients with locally advanced breast cancer: Correlation with tumor biological subtypes and pathological response after therapy.
    Ballesio L; Gigli S; Di Pastena F; Giraldi G; Manganaro L; Anastasi E; Catalano C
    Tumour Biol; 2017 Mar; 39(3):1010428317694540. PubMed ID: 28347225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic resonance imaging patterns of tumor regression after neoadjuvant chemotherapy in breast cancer patients: correlation with pathological response grading system based on tumor cellularity.
    Kim TH; Kang DK; Yim H; Jung YS; Kim KS; Kang SY
    J Comput Assist Tomogr; 2012; 36(2):200-6. PubMed ID: 22446360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Magnetic resonance imaging patterns of tumor regression in breast cancer patients after neo-adjuvant chemotherapy, and an analysis of the influencing factors.
    Li M; Xu B; Shao Y; Liu H; Du B; Yuan J
    Breast J; 2017 Nov; 23(6):656-662. PubMed ID: 28397346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer.
    Goorts B; Dreuning KMA; Houwers JB; Kooreman LFS; Boerma EG; Mann RM; Lobbes MBI; Smidt ML
    Breast Cancer Res; 2018 Apr; 20(1):34. PubMed ID: 29669584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRI-based tumor shrinkage patterns after early neoadjuvant therapy in breast cancer: correlation with molecular subtypes and pathological response after therapy.
    Wang M; Du S; Gao S; Zhao R; Liu S; Jiang W; Peng C; Chai R; Zhang L
    Breast Cancer Res; 2024 Feb; 26(1):26. PubMed ID: 38347619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diffusion-weighted imaging in assessing pathological response of tumor in breast cancer subtype to neoadjuvant chemotherapy.
    Liu S; Ren R; Chen Z; Wang Y; Fan T; Li C; Zhang P
    J Magn Reson Imaging; 2015 Sep; 42(3):779-87. PubMed ID: 25580585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pattern of Tumor Shrinkage during Neoadjuvant Chemotherapy Is Associated with Prognosis in Low-Grade Luminal Early Breast Cancer.
    Fukada I; Araki K; Kobayashi K; Shibayama T; Takahashi S; Gomi N; Kokubu Y; Oikado K; Horii R; Akiyama F; Iwase T; Ohno S; Hatake K; Sata N; Ito Y
    Radiology; 2018 Jan; 286(1):49-57. PubMed ID: 28737968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnetic resonance imaging in breast cancer treated with neoadjuvant chemotherapy: radiologic-pathologic correlation of the response and disease-free survival depending on molecular subtype.
    Cruz Ciria S; Jiménez Aragón F; García Mur C; Esteban Cuesta H; Gros Bañeres B
    Radiologia; 2014; 56(6):524-32. PubMed ID: 23294850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?
    Okamoto S; Yamada T; Kanemaki Y; Kojima Y; Tsugawa K; Nakajima Y
    Breast Cancer; 2016 Sep; 23(5):789-96. PubMed ID: 26437647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast MR imaging changes after neoadjuvant chemotherapy: correlation with molecular subtypes.
    Marcos de Paz LM; Tejerina Bernal A; Arranz Merino ML; Calvo de Juan V
    Radiologia; 2012; 54(5):442-8. PubMed ID: 21937065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Tumor Response After Neoadjuvant Chemotherapy in Breast Cancer Patients: Correlation Between Dynamic Contrast-enhanced Magnetic Resonance Imaging and Pathologic Tumor Cellularity.
    Choi WJ; Kim WK; Shin HJ; Cha JH; Chae EY; Kim HH
    Clin Breast Cancer; 2018 Feb; 18(1):e115-e121. PubMed ID: 28890184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast-conserving surgery after chemotherapy: value of MDCT for determining tumor distribution and shrinkage pattern.
    Tozaki M; Kobayashi T; Uno S; Aiba K; Takeyama H; Shioya H; Tabei I; Toriumi Y; Suzuki M; Fukuda K
    AJR Am J Roentgenol; 2006 Feb; 186(2):431-9. PubMed ID: 16423949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.
    Park JS; Moon WK; Lyou CY; Cho N; Kang KW; Chung JK
    Acta Radiol; 2011 Feb; 52(1):21-8. PubMed ID: 21498321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive Clinicopathologic and Dynamic Contrast-Enhanced MRI Findings for Tumor Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Eom HJ; Cha JH; Choi WJ; Chae EY; Shin HJ; Kim HH
    AJR Am J Roentgenol; 2017 Jun; 208(6):W225-W230. PubMed ID: 28350486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct comparison of magnetic resonance imaging and pathological shrinkage patterns of triple-negative breast cancer after neoadjuvant chemotherapy.
    Yoshikawa K; Ishida M; Kan N; Yanai H; Tsuta K; Sekimoto M; Sugie T
    World J Surg Oncol; 2020 Jul; 18(1):177. PubMed ID: 32693794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of MRI and PET/CT after neoadjuvant chemotherapy in breast cancer patients: correlation with pathological response grading system based on tumor cellularity.
    Kim T; Kang DK; An YS; Yim H; Jung YS; Kim KS; Kang SY; Kim TH
    Acta Radiol; 2014 May; 55(4):399-408. PubMed ID: 23963151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Systemic Therapy in Breast Cancer: Association of Contrast-enhanced MR Imaging Findings, Diffusion-weighted Imaging Findings, and Tumor Subtype with Tumor Response.
    Santamaría G; Bargalló X; Fernández PL; Farrús B; Caparrós X; Velasco M
    Radiology; 2017 Jun; 283(3):663-672. PubMed ID: 27875106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between intrinsic subtypes and tumor responses to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
    Ooe A; Takahara S; Sumiyoshi K; Yamamoto H; Kawai J; Shiba E
    Breast Dis; 2012; 34(1):9-17. PubMed ID: 23507670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A study on the predictive and evaluational value of molecular subtypes and dynamic contrast-enhanced magnetic resonance imaging of neoadjuvant chemotherapy for breast cancer].
    Liu WQ; Ye JM; Xu L; Liu Q; Zhao JX; Duan XN; Liu YH
    Zhonghua Wai Ke Za Zhi; 2013 Aug; 51(8):706-9. PubMed ID: 24252676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting Neoadjuvant Chemotherapy in Nonconcentric Shrinkage Pattern of Breast Cancer Using 1H-Magnetic Resonance Spectroscopic Imaging.
    Zhou J; Qiao PG; Zhang HT; Li GJ; Jiang ZF
    J Comput Assist Tomogr; 2018; 42(1):12-18. PubMed ID: 28708720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.